Skip to main content
  • ASM
    • Antimicrobial Agents and Chemotherapy
    • Applied and Environmental Microbiology
    • Clinical Microbiology Reviews
    • Clinical and Vaccine Immunology
    • EcoSal Plus
    • Infection and Immunity
    • Journal of Bacteriology
    • Journal of Clinical Microbiology
    • Journal of Microbiology & Biology Education
    • Journal of Virology
    • mBio
    • Microbiology and Molecular Biology Reviews
    • Microbiology Resource Announcements
    • Microbiology Spectrum
    • Molecular and Cellular Biology
    • mSphere
    • mSystems
  • Log in
  • My alerts
  • My Cart

Main menu

  • Home
  • Articles
    • Current Issue
    • Accepted Manuscripts
    • COVID-19 Special Collection
    • Minireviews
    • JVI Classic Spotlights
    • Archive
  • For Authors
    • Submit a Manuscript
    • Scope
    • Editorial Policy
    • Submission, Review, & Publication Processes
    • Organization and Format
    • Errata, Author Corrections, Retractions
    • Illustrations and Tables
    • Nomenclature
    • Abbreviations and Conventions
    • Publication Fees
    • Ethics Resources and Policies
  • About the Journal
    • About JVI
    • Editor in Chief
    • Editorial Board
    • For Reviewers
    • For the Media
    • For Librarians
    • For Advertisers
    • Alerts
    • RSS
    • FAQ
  • Subscribe
    • Members
    • Institutions
  • ASM
    • Antimicrobial Agents and Chemotherapy
    • Applied and Environmental Microbiology
    • Clinical Microbiology Reviews
    • Clinical and Vaccine Immunology
    • EcoSal Plus
    • Infection and Immunity
    • Journal of Bacteriology
    • Journal of Clinical Microbiology
    • Journal of Microbiology & Biology Education
    • Journal of Virology
    • mBio
    • Microbiology and Molecular Biology Reviews
    • Microbiology Resource Announcements
    • Microbiology Spectrum
    • Molecular and Cellular Biology
    • mSphere
    • mSystems

User menu

  • Log in
  • My alerts
  • My Cart

Search

  • Advanced search
Journal of Virology
publisher-logosite-logo

Advanced Search

  • Home
  • Articles
    • Current Issue
    • Accepted Manuscripts
    • COVID-19 Special Collection
    • Minireviews
    • JVI Classic Spotlights
    • Archive
  • For Authors
    • Submit a Manuscript
    • Scope
    • Editorial Policy
    • Submission, Review, & Publication Processes
    • Organization and Format
    • Errata, Author Corrections, Retractions
    • Illustrations and Tables
    • Nomenclature
    • Abbreviations and Conventions
    • Publication Fees
    • Ethics Resources and Policies
  • About the Journal
    • About JVI
    • Editor in Chief
    • Editorial Board
    • For Reviewers
    • For the Media
    • For Librarians
    • For Advertisers
    • Alerts
    • RSS
    • FAQ
  • Subscribe
    • Members
    • Institutions
Pathogenesis and Immunity

GB Virus C Coinfections in West African Ebola Patients

Michael Lauck, Adam L. Bailey, Kristian G. Andersen, Tony L. Goldberg, Pardis C. Sabeti, David H. O'Connor
G. Silvestri, Editor
Michael Lauck
aDepartment of Pathology and Laboratory Medicine, University of Wisconsin—Madison, Madison, Wisconsin, USA
bWisconsin National Primate Research Center, Madison, Wisconsin, USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Adam L. Bailey
aDepartment of Pathology and Laboratory Medicine, University of Wisconsin—Madison, Madison, Wisconsin, USA
bWisconsin National Primate Research Center, Madison, Wisconsin, USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Kristian G. Andersen
cThe Broad Institute of MIT and Harvard, Cambridge, Massachusetts, USA
dCenter for Systems Biology, Department of Organismic and Evolutionary Biology, Harvard University, Cambridge, Massachusetts, USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Tony L. Goldberg
bWisconsin National Primate Research Center, Madison, Wisconsin, USA
eDepartment of Pathobiological Sciences, University of Wisconsin—Madison, Madison, Wisconsin, USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Pardis C. Sabeti
cThe Broad Institute of MIT and Harvard, Cambridge, Massachusetts, USA
dCenter for Systems Biology, Department of Organismic and Evolutionary Biology, Harvard University, Cambridge, Massachusetts, USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
David H. O'Connor
aDepartment of Pathology and Laboratory Medicine, University of Wisconsin—Madison, Madison, Wisconsin, USA
bWisconsin National Primate Research Center, Madison, Wisconsin, USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
G. Silvestri
Roles: Editor
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
DOI: 10.1128/JVI.02752-14
  • Article
  • Figures & Data
  • Info & Metrics
  • PDF
Loading

ABSTRACT

In 49 patients with known Ebola virus disease outcomes during the ongoing outbreak in Sierra Leone, 13 were coinfected with the immunomodulatory pegivirus GB virus C (GBV-C). Fifty-three percent of these GBV-C+ patients survived; in contrast, only 22% of GBV-C− patients survived. Both survival and GBV-C status were associated with age, with older patients having lower survival rates and intermediate-age patients (21 to 45 years) having the highest rate of GBV-C infection. Understanding the separate and combined effects of GBV-C and age on Ebola virus survival may lead to new treatment and prevention strategies, perhaps through age-related pathways of immune activation.

TEXT

As of this writing, there have been 14,413 confirmed and probable infections and 5,177 deaths in the ongoing and worsening Ebola virus (EBOV) disease outbreak in West Africa (1). Recently, EBOV sequences from Sierra Leone were obtained by unbiased deep sequencing. These patients represented approximately 70% of patients with Ebola virus disease in Sierra Leone from late May to mid-June of 2014 (2).

In the three countries (Sierra Leone, Liberia, and Guinea) where the Ebola virus outbreak is concentrated, GB virus C (GBV-C, also known as human pegivirus) infects between 10 and 28% of individuals (3–6). Although GBV-C causes a prolonged high-titer viremia, GBV-C infection is largely considered to be benign (7, 8). Intriguingly, several epidemiological studies have associated GBV-C infection with lower mortality in HIV-positive people (9–12; see reference 13 for a meta-analysis). Although potential mechanisms explaining this association are still under investigation, a growing body of evidence suggests that GBV-C prevents aberrant immune activation that is a hallmark of HIV pathogenesis and disease progression (i.e., AIDS) (see reference 14 for a review).

We reasoned that the relatively high prevalence of GBV-C in West Africa would result in a significant number of coinfections with EBOV. To examine GBV-C coinfections with EBOV, deep-sequencing data initially published in reference 2 were downloaded from the NCBI Sequence Read Archive (SRA), sequencing run (SRR) files were converted into fastq files using the SRA toolkit, and SRR identifiers (IDs) were correlated with patient sample IDs using information from supplemental Table S2 in reference 2. Further analysis was confined to the 49 patients for whom EBOV infection outcome, age, and gender information were available (see Fig. S2 in the supplemental material in reference 2; also unpublished data). Samples for which two independent library preparations were performed or which were collected from the same individual at multiple time points were merged into single fastq files. fastq files were then imported into CLC Genomics Workbench 7 and short (<90-bp) and low-quality (Phred quality score <Q30) reads were removed. Samples labeled as potential duplicates in supplemental Table S2 of reference 2 were excluded from the analysis. Reads from all patients were aligned with moderate stringency (length fraction, 0.8; similarity fraction, 0.8; mismatch cost, 2; insertion and deletion cost, 3) against a full-genome GBV-C genotype 1 reference, the predominant genotype in West Africa (15) (GenBank accession number HGU36380). Up to 79,619 reads mapped to GBV-C per individual (Table 1).

View this table:
  • View inline
  • View popup
TABLE 1

EBOV patients coinfected with GBV-C

A low level of carryover contamination is common in unbiased deep-sequencing experiments. We were therefore concerned that samples with low numbers of GBV-C reads might represent carryover from other samples with high levels of GBV-C. To more rigorously define samples as GBV-C positive or negative, we determined the GBV-C consensus sequence for each sample. We then remapped the reads from each sample against consensus sequences from all samples with high stringency (length fraction, 0.98; similarity fraction, 0.98; mismatch cost, 2; insertion and deletion cost, 3) and discarded reads that mapped to multiple consensus sequences. Twelve individuals had unambiguous evidence of GBV-C viremia supported by at least 100 uniquely mapped reads covering between 63 and 100% of the genome (Tables 1 and 2). A 13th individual (G3764) was putatively categorized as GBV-C+ on the basis of 55 uniquely mapped reads, resulting in 38% coverage across the genome.

View this table:
  • View inline
  • View popup
TABLE 2

EBOV patients not coinfected with GBV-C

The 2014 EBOV sequences from Sierra Leone were on average 99.98% [99.98% to 100%] identical in pairwise comparisons across the genome (data not shown), which is consistent with the recency of this outbreak. In contrast, GBV-C sequences shared on average 91% (86.96 to 98.46%) nucleotide identity (Table 3), suggesting preexisting GBV-C infections rather than cotransmission with EBOV.

View this table:
  • View inline
  • View popup
TABLE 3

Pairwise comparison of percentages of nucleotide identity for GBV-C consensus sequences

Mortality in this cohort of 49 patients with sequence-confirmed EBOV infection was 69% overall, which is comparable to the 65% mortality reported for definitive infections in Sierra Leone before 18 August 2014 (1). Only 6/13 (46%) GBV-C+ individuals died, whereas 28/36 (78%) GBV-C− individuals died. Univariate analyses (Table 4) showed that older age was associated with higher mortality (OR, 1.06; P = 0.0124) and that GBV-C+ status was associated with lower mortality (OR = 0.25; P = 0.0402). However, when these factors were considered together in a multivariate analysis (Table 4), GBV-C status became nonsignificant (OR = 0.25; P = 0.0835), likely reflecting a confounding effect of age. Our finding of a relationship between older age and higher mortality is consistent with a recently published study (16). However, GBV-C infection follows a different pattern, being most common in people aged 21 to 45 years (Fig. 1). Thus, age is associated with both EBOV survival and GBV-C status, but the pattern of association is different in each case.

View this table:
  • View inline
  • View popup
TABLE 4

Factors associated with mortality in EBOV+ patientsa

FIG 1
  • Open in new tab
  • Download powerpoint
FIG 1

Ebola virus mortality and GBV-C coinfection status by age.

There were both epidemiological and technical aspects of this study that could not be controlled. For example, potentially confounding variables, such as comorbidities, rapidity of diagnosis, and relationships among patients, were not available. Furthermore, the samples were collected opportunistically, possibly introducing selection bias. It is also possible that we were not able to detect low-titer GBV-C viremia in some patients. Because sequencing reads were generated in an “unbiased” fashion, patients with very high EBOV titers may have “swamped” the sample, effectively reducing the number of GBV-C reads. We believe that this is unlikely because (i) we detected GBV-C in patients with EBOV plasma loads of >108 (see supplemental Fig. S2 in reference 2) and (ii) in previous studies, we have detected multiple viruses from a single sample using a similar methodology, even in samples where at least one virus was highly concentrated (17–20). Recovery of unique reads targeting the majority of the viral genome provide unequivocal evidence for GBV-C infection in all but one of the samples; however, in the one sample where less than half of the genome is covered, verification of GBV-C status using an independent assay (e.g., reverse transcription-quantitative PCR [RT-qPCR]) would be ideal but is not currently possible.

Nonetheless, these results demonstrate that approximately 27% of EBOV patients in this cohort are coinfected with GBV-C, an immunomodulatory virus that attenuates the pathogenesis of HIV. The association between GBV-C status and Ebola virus disease survival is intriguing, although confounded by age. We speculate that GBV-C may interact with the host immune system in ways that modulate the overexuberant immune response characteristic of EBOV-related pathogenesis (21–27). However, our analyses are also consistent with a primary effect of age on both Ebola virus disease-related survival and GBV-C infection. Resolving the direction of causality would require additional data on the time course of infection and coinfection, as well as direct measures of immunity.

EBOV and GBV-C appear to infect different types of immune cells. EBOV infects primarily myeloid-lineage cells (28–31), while GBV-C appears to target lymphoid-lineage cells (32, 33). The interaction of immune cell populations—both locally in lymphoid tissues and systemically via secreted factors—provides a biologically plausible mechanism for an interaction between GBV-C and EBOV. If GBV-C infection attenuates EBOV pathogenesis, it is possible that this occurs through modulation of the host immune response. In the context of HIV infection, GBV-C has been associated with a reduced production of proinflammatory cytokines and a reduction in T-cell activation in vivo and in vitro (34–44). Conversely, robust production of proinflammatory cytokines and lymphocyte activation followed by massive T-cell death are thought to play a major role in EBOV pathogenesis and have been associated with poor clinical outcome in retrospective studies (21–27).

Although our data are preliminary and potentially influenced by confounding variables, the results that we present here indicate that further study of GBV-C/EBOV coinfection may be warranted. Such investigations should endeavor to follow patients of different ages longitudinally and to collect immunological data, with the goal of establishing the temporal sequence of events that leads to EBOV-related survival and mortality, with and without coinfecting GBV-C.

Nucleotide sequence accession number.We have made consensus GBV-C sequences available in GenBank (accession numbers KM670096 to KM670110).

ACKNOWLEDGMENTS

Five coauthors of the study that provided the original data used in the manuscript lost their lives to Ebola (45). This paper would not have been possible without their courageous efforts. We thank all the authors of the original paper (2) for making their source data publicly available for reanalysis. We thank Erin Bailey, Thomas Friedrich, and Esper Kallas for helpful discussion.

This work was funded by the NIH (grants R01 AI077376-01 and R01 AI077376). This publication was made possible in part by a grant (P51 RR000167) from the Office of Research Infrastructure Programs (ORIP), a component of the National Institutes of Health (NIH), to the Wisconsin National Primate Research Center (WNPRC), University of Wisconsin—Madison. This research was conducted in part at a facility constructed with support from the Research Facilities Improvement Program (grants RR15459-01 and RR020141-01). A.L.B. performed this work with support from the University of Wisconsin's Medical Scientist Training Program (MSTP) (grant T32 GM008692) and a National Research Service Award (NRSA) through the Microbes in Health and Disease (MHD) training program at the University of Wisconsin (T32 AI055397). We thank the University of Wisconsin Department of Pathology and Laboratory Medicine and the WNPRC for funding and the use of its facilities and services. The funders of this research had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.

FOOTNOTES

    • Received 25 September 2014.
    • Accepted 23 November 2014.
    • Accepted manuscript posted online 3 December 2014.
  • Copyright © 2015, American Society for Microbiology. All Rights Reserved.

REFERENCES

  1. 1.↵
    World Health Organization. 14 November 2014. Ebola response roadmap—situation report update. World Health Organization, Geneva, Switzerland. http://www.who.int/csr/disease/ebola/situation-reports/en/.
  2. 2.↵
    1. Gire SK,
    2. Goba A,
    3. Andersen KG,
    4. Sealfon RS,
    5. Park DJ,
    6. Kanneh L,
    7. Jalloh S,
    8. Momoh M,
    9. Fullah M,
    10. Dudas G,
    11. Wohl S,
    12. Moses LM,
    13. Yozwiak NL,
    14. Winnicki S,
    15. Matranga CB,
    16. Malboeuf CM,
    17. Qu J,
    18. Gladden AD,
    19. Schaffner SF,
    20. Yang X,
    21. Jiang PP,
    22. Nekoui M,
    23. Colubri A,
    24. Coomber MR,
    25. Fonnie M,
    26. Moigboi A,
    27. Gbakie M,
    28. Kamara FK,
    29. Tucker V,
    30. Konuwa E,
    31. Saffa S,
    32. Sellu J,
    33. Jalloh AA,
    34. Kovoma A,
    35. Koninga J,
    36. Mustapha I,
    37. Kargbo K,
    38. Foday M,
    39. Yillah M,
    40. Kanneh F,
    41. Robert W,
    42. Massally JL,
    43. Chapman SB,
    44. Bochicchio J,
    45. Murphy C,
    46. Nusbaum C,
    47. Young S,
    48. Birren BW,
    49. Grant DS,
    50. Scheiffelin JS,
    51. Lander ES,
    52. Happi C,
    53. Gevao SM,
    54. Gnirke A,
    55. Rambaut A,
    56. Garry RF,
    57. Khan SH,
    58. Sabeti PC
    . 2014. Genomic surveillance elucidates Ebola virus origin and transmission during the 2014 outbreak. Science 345:1369–1372. doi:10.1126/science.1259657.
    OpenUrlAbstract/FREE Full Text
  3. 3.↵
    1. Li C,
    2. Collini P,
    3. Danso K,
    4. Owusu-Ofori S,
    5. Dompreh A,
    6. Candotti D,
    7. Opare-Sem O,
    8. Allain JP
    . 2006. GB virus C and HIV-1 RNA load in single virus and co-infected West African individuals. AIDS 20:379–386. doi:10.1097/01.aids.0000200536.79360.03.
    OpenUrlCrossRefPubMedWeb of Science
  4. 4.↵
    1. Compston LI,
    2. Li C,
    3. Sarkodie F,
    4. Owusu-Ofori S,
    5. Opare-Sem O,
    6. Allain JP
    . 2009. Prevalence of persistent and latent viruses in untreated patients infected with HIV-1 from Ghana, West Africa. J Med Virol 81:1860–1868. doi:10.1002/jmv.21614.
    OpenUrlCrossRefPubMed
  5. 5.↵
    1. Sathar M,
    2. Soni P,
    3. York D
    . 2000. GB virus C/hepatitis G virus (GBV-C/HGV): still looking for a disease. Int J Exp Pathol 81:305–322. doi:10.1046/j.1365-2613.2000.00166.x.
    OpenUrlCrossRefPubMed
  6. 6.↵
    1. Mohr EL,
    2. Stapleton JT
    . 2009. GB virus type C interactions with HIV: the role of envelope glycoproteins. J Viral Hepat 16:757–768. doi:10.1111/j.1365-2893.2009.01194.x.
    OpenUrlCrossRefPubMedWeb of Science
  7. 7.↵
    1. Stapleton JT,
    2. Foung S,
    3. Muerhoff AS,
    4. Bukh J,
    5. Simmonds P
    . 2011. The GB viruses: a review and proposed classification of GBV-A, GBV-C (HGV), and GBV-D in genus Pegivirus within the family Flaviviridae. J Gen Virol 92:233–246. doi:10.1099/vir.0.027490-0.
    OpenUrlCrossRefPubMedWeb of Science
  8. 8.↵
    1. Alter HJ
    . 1997. G-pers creepers, where'd you get those papers? A reassessment of the literature on the hepatitis G virus. Transfusion 37:569–572.
    OpenUrlCrossRefPubMedWeb of Science
  9. 9.↵
    1. Williams CF,
    2. Klinzman D,
    3. Yamashita TE,
    4. Xiang J,
    5. Polgreen PM,
    6. Rinaldo C,
    7. Liu C,
    8. Phair J,
    9. Margolick JB,
    10. Zdunek D,
    11. Hess G,
    12. Stapleton JT
    . 2004. Persistent GB virus C infection and survival in HIV-infected men. N Engl J Med 350:981–990. doi:10.1056/NEJMoa030107.
    OpenUrlCrossRefPubMedWeb of Science
  10. 10.↵
    1. Xiang J,
    2. Wünschmann S,
    3. Diekema DJ,
    4. Klinzman D,
    5. Patrick KD,
    6. George SL,
    7. Stapleton JT
    . 2001. Effect of coinfection with GB virus C on survival among patients with HIV infection. N Engl J Med 345:707–714. doi:10.1056/NEJMoa003364.
    OpenUrlCrossRefPubMedWeb of Science
  11. 11.↵
    1. Vahidnia F,
    2. Petersen M,
    3. Stapleton JT,
    4. Rutherford GW,
    5. Busch M,
    6. Custer B
    . 2012. Acquisition of GB virus type C and lower mortality in patients with advanced HIV disease. Clin Infect Dis 55:1012–1019. doi:10.1093/cid/cis589.
    OpenUrlCrossRefPubMed
  12. 12.↵
    1. Tillmann HL,
    2. Heiken H,
    3. Knapik-Botor A,
    4. Heringlake S,
    5. Ockenga J,
    6. Wilber JC,
    7. Goergen B,
    8. Detmer J,
    9. McMorrow M,
    10. Stoll M,
    11. Schmidt RE,
    12. Manns MP
    . 2001. Infection with GB virus C and reduced mortality among HIV-infected patients. N Engl J Med 345:715–724. doi:10.1056/NEJMoa010398.
    OpenUrlCrossRefPubMedWeb of Science
  13. 13.↵
    1. Zhang W,
    2. Chaloner K,
    3. Tillmann HL,
    4. Williams CF,
    5. Stapleton JT
    . 2006. Effect of early and late GB virus C viraemia on survival of HIV-infected individuals: a meta-analysis. HIV Med 7:173–180. doi:10.1111/j.1468-1293.2006.00366.x.
    OpenUrlCrossRefPubMedWeb of Science
  14. 14.↵
    1. Bhattarai N,
    2. Stapleton JT
    . 2012. GB virus C: the good boy virus? Trends Microbiol 20:124–130. doi:10.1016/j.tim.2012.01.004.
    OpenUrlCrossRefPubMedWeb of Science
  15. 15.↵
    1. Tucker TJ,
    2. Smuts HE
    . 2000. GBV-C/HGV genotypes: proposed nomenclature for genotypes 1–5. J Med Virol 62:82–83. doi:10.1002/1096-9071(200009)62:1<82::AID-JMV12>3.0.CO;2-J.
    OpenUrlCrossRefPubMedWeb of Science
  16. 16.↵
    1. Schieffelin JS,
    2. Shaffer JG,
    3. Goba A,
    4. Gbakie M,
    5. Gire SK,
    6. Colubri A,
    7. Sealfon RS,
    8. Kanneh L,
    9. Moigboi A,
    10. Momoh M,
    11. Fullah M,
    12. Moses LM,
    13. Brown BL,
    14. Andersen KG,
    15. Winnicki S,
    16. Schaffner SF,
    17. Park DJ,
    18. Yozwiak NL,
    19. Jiang PP,
    20. Kargbo D,
    21. Jalloh S,
    22. Fonnie M,
    23. Sinnah V,
    24. French I,
    25. Kovoma A,
    26. Kamara FK,
    27. Tucker V,
    28. Konuwa E,
    29. Sellu J,
    30. Mustapha I,
    31. Foday M,
    32. Yillah M,
    33. Kanneh F,
    34. Saffa S,
    35. Massally JL,
    36. Boisen ML,
    37. Branco LM,
    38. Vandi MA,
    39. Grant DS,
    40. Happi C,
    41. Gevao SM,
    42. Fletcher TE,
    43. Fowler RA,
    44. Bausch DG,
    45. Sabeti PC,
    46. Khan SH,
    47. Garry RF
    . 2014. Clinical illness and outcomes in patients with Ebola in Sierra Leone. N Engl J Med 371:2092–2100. doi:10.1056/NEJMoa1411680.
    OpenUrlCrossRefPubMed
  17. 17.↵
    1. Sibley SD,
    2. Lauck M,
    3. Bailey AL,
    4. Hyeroba D,
    5. Tumukunde A,
    6. Weny G,
    7. Chapman CA,
    8. O'Connor DH,
    9. Goldberg TL,
    10. Friedrich TC
    . 2014. Discovery and characterization of distinct simian pegiviruses in three wild African Old World monkey species. PLoS One 9:e98569. doi:10.1371/journal.pone.0098569.
    OpenUrlCrossRefPubMed
  18. 18.↵
    1. Lauck M,
    2. Sibley SD,
    3. Hyeroba D,
    4. Tumukunde A,
    5. Weny G,
    6. Chapman CA,
    7. Ting N,
    8. Switzer WM,
    9. Kuhn JH,
    10. Friedrich TC,
    11. O'Connor DH,
    12. Goldberg TL
    . 2013. Exceptional simian hemorrhagic fever virus diversity in a Wild African primate community. J Virol 87:688–691. doi:10.1128/JVI.02433-12.
    OpenUrlAbstract/FREE Full Text
  19. 19.↵
    1. Bailey AL,
    2. Lauck M,
    3. Weiler A,
    4. Sibley SD,
    5. Dinis JM,
    6. Bergman Z,
    7. Nelson CW,
    8. Correll M,
    9. Gleicher M,
    10. Hyeroba D,
    11. Tumukunde A,
    12. Weny G,
    13. Chapman C,
    14. Kuhn JH,
    15. Hughes AL,
    16. Friedrich TC,
    17. Goldberg TL,
    18. O'Connor DH
    . 2014. High genetic diversity and adaptive potential of two simian hemorrhagic fever viruses in a wild primate population. PLoS One 9:e90714. doi:10.1371/journal.pone.0090714.
    OpenUrlCrossRefPubMed
  20. 20.↵
    1. Bailey AL,
    2. Lauck M,
    3. Sibley SD,
    4. Pecotte J,
    5. Rice K,
    6. Weny G,
    7. Tumukunde A,
    8. Hyeroba D,
    9. Greene J,
    10. Correll M,
    11. Gleicher M,
    12. Friedrich TC,
    13. Jahrling PB,
    14. Kuhn JH,
    15. Goldberg TL,
    16. Rogers J,
    17. O'Connor DH
    . 3 September 2014. Two novel simian arteriviruses in captive and wild baboons (Papio spp.). J Virol doi:10.1128/JVI.02203-14.
    OpenUrlAbstract/FREE Full Text
  21. 21.↵
    1. Villinger F,
    2. Rollin PE,
    3. Brar SS,
    4. Chikkala NF,
    5. Winter J,
    6. Sundstrom JB,
    7. Zaki SR,
    8. Swanepoel R,
    9. Ansari AA,
    10. Peters CJ
    . 1999. Markedly elevated levels of interferon (IFN)-gamma, IFN-alpha, interleukin (IL)-2, IL-10, and tumor necrosis factor-alpha associated with fatal Ebola virus infection. J Infect Dis 179(Suppl 1):S188–S191. doi:10.1086/514283.
    OpenUrlCrossRefPubMedWeb of Science
  22. 22.↵
    1. Geisbert TW,
    2. Hensley LE,
    3. Gibb TR,
    4. Steele KE,
    5. Jaax NK,
    6. Jahrling PB
    . 2000. Apoptosis induced in vitro and in vivo during infection by Ebola and Marburg viruses. Lab Invest 80:171–186. doi:10.1038/labinvest.3780021.
    OpenUrlCrossRefPubMedWeb of Science
  23. 23.↵
    1. Baize S,
    2. Leroy EM,
    3. Georges AJ,
    4. Georges-Courbot MC,
    5. Capron M,
    6. Bedjabaga I,
    7. Lansoud-Soukate J,
    8. Mavoungou E
    . 2002. Inflammatory responses in Ebola virus-infected patients. Clin Exp Immunol 128:163–168. doi:10.1046/j.1365-2249.2002.01800.x.
    OpenUrlCrossRefPubMedWeb of Science
  24. 24.↵
    1. Hensley LE,
    2. Young HA,
    3. Jahrling PB,
    4. Geisbert TW
    . 2002. Proinflammatory response during Ebola virus infection of primate models: possible involvement of the tumor necrosis factor receptor superfamily. Immunol Lett 80:169–179. doi:10.1016/S0165-2478(01)00327-3.
    OpenUrlCrossRefPubMedWeb of Science
  25. 25.↵
    1. Sanchez A,
    2. Lukwiya M,
    3. Bausch D,
    4. Mahanty S,
    5. Sanchez AJ,
    6. Wagoner KD,
    7. Rollin PE
    . 2004. Analysis of human peripheral blood samples from fatal and nonfatal cases of Ebola (Sudan) hemorrhagic fever: cellular responses, virus load, and nitric oxide levels. J Virol 78:10370–10377. doi:10.1128/JVI.78.19.10370-10377.2004.
    OpenUrlAbstract/FREE Full Text
  26. 26.↵
    1. Baize S,
    2. Leroy EM,
    3. Georges-Courbot MC,
    4. Capron M,
    5. Lansoud-Soukate J,
    6. Debre P,
    7. Fisher-Hoch SP,
    8. McCormick JB,
    9. Georges AJ
    . 1999. Defective humoral responses and extensive intravascular apoptosis are associated with fatal outcome in Ebola virus-infected patients. Nat Med 5:423–426. doi:10.1038/7422.
    OpenUrlCrossRefPubMedWeb of Science
  27. 27.↵
    1. Ignatiev GM,
    2. Dadaeva AA,
    3. Luchko SV,
    4. Chepurnov AA
    . 2000. Immune and pathophysiological processes in baboons experimentally infected with Ebola virus adapted to guinea pigs. Immunol Lett 71:131–140. doi:10.1016/S0165-2478(99)00169-8.
    OpenUrlCrossRefPubMedWeb of Science
  28. 28.↵
    1. Ryabchikova EI,
    2. Kolesnikova LV,
    3. Luchko SV
    . 1999. An analysis of features of pathogenesis in two animal models of Ebola virus infection. J Infect Dis 179:S199–S202. doi:10.1086/514293.
    OpenUrlCrossRefPubMedWeb of Science
  29. 29.↵
    1. Geisbert TW,
    2. Hensley LE,
    3. Larsen T,
    4. Young HA,
    5. Reed DS,
    6. Geisbert JB,
    7. Scott DP,
    8. Kagan E,
    9. Jahrling PB,
    10. Davis KJ
    . 2003. Pathogenesis of Ebola hemorrhagic fever in cynomolgus macaques: evidence that dendritic cells are early and sustained targets of infection. Am J Pathol 163:2347–2370. doi:10.1016/S0002-9440(10)63591-2.
    OpenUrlCrossRefPubMedWeb of Science
  30. 30.↵
    1. Geisbert TW,
    2. Young HA,
    3. Jahrling PB,
    4. Davis KJ,
    5. Larsen T,
    6. Kagan E,
    7. Hensley LE
    . 2003. Pathogenesis of Ebola hemorrhagic fever in primate models: evidence that hemorrhage is not a direct effect of virus-induced cytolysis of endothelial cells. Am J Pathol 163:2371–2382. doi:10.1016/S0002-9440(10)63592-4.
    OpenUrlCrossRefPubMedWeb of Science
  31. 31.↵
    1. Feldmann H,
    2. Bugany H,
    3. Mahner F,
    4. Klenk HD,
    5. Drenckhahn D,
    6. Schnittler HJ
    . 1996. Filovirus-induced endothelial leakage triggered by infected monocytes/macrophages. J Virol 70:2208–2214.
    OpenUrlAbstract/FREE Full Text
  32. 32.↵
    1. Chivero ET,
    2. Bhattarai N,
    3. Rydze RT,
    4. Winters MA,
    5. Holodniy M,
    6. Stapleton J
    . 2014. Human Pegivirus (HPgV or GB virus C) RNA is found in multiple blood mononuclear cells in vivo and serum-derived viral RNA containing particles are infectious in vitro. J Gen Virol 95:1307–1319. doi:10.1099/vir.0.063016-0.
    OpenUrlCrossRefPubMedWeb of Science
  33. 33.↵
    1. George SL,
    2. Varmaz D,
    3. Stapleton JT
    . 2006. GB virus C replicates in primary T and B lymphocytes. J Infect Dis 193:451–454. doi:10.1086/499435.
    OpenUrlCrossRefPubMed
  34. 34.↵
    1. Bhattarai N,
    2. McLinden JH,
    3. Xiang J,
    4. Landay AL,
    5. Chivero ET,
    6. Stapleton JT
    . 2013. GB virus C particles inhibit T cell activation via envelope E2 protein-mediated inhibition of TCR signaling. J Immunol 190:6351–6359. doi:10.4049/jimmunol.1300589.
    OpenUrlAbstract/FREE Full Text
  35. 35.↵
    1. Bhattarai N,
    2. McLinden JH,
    3. Xiang J,
    4. Kaufman TM,
    5. Stapleton JT
    . 2012. GB virus C envelope protein E2 inhibits TCR-induced IL-2 production and alters IL-2-signaling pathways. J Immunol 189:2211–2216. doi:10.4049/jimmunol.1201324.
    OpenUrlAbstract/FREE Full Text
  36. 36.↵
    1. Bhattarai N,
    2. Rydze RT,
    3. Chivero ET,
    4. Stapleton JT
    . 2012. GB virus C viremia is associated with higher levels of double-negative T cells and lower T-cell activation in HIV-infected individuals receiving antiretroviral therapy. J Infect Dis 206:1469–1472. doi:10.1093/infdis/jis515.
    OpenUrlCrossRefPubMed
  37. 37.↵
    1. Maidana-Giret MT,
    2. Silva TM,
    3. Sauer MM,
    4. Tomiyama H,
    5. Levi JE,
    6. Bassichetto KC,
    7. Nishiya A,
    8. Diaz RS,
    9. Sabino EC,
    10. Palacios R,
    11. Kallas EG
    . 2009. GB virus type C infection modulates T-cell activation independently of HIV-1 viral load. AIDS 23:2277–2287. doi:10.1097/QAD.0b013e32832d7a11.
    OpenUrlCrossRefPubMedWeb of Science
  38. 38.↵
    1. Moenkemeyer M,
    2. Schmidt RE,
    3. Wedemeyer H,
    4. Tillmann HL,
    5. Heiken H
    . 2008. GBV-C coinfection is negatively correlated to Fas expression and Fas-mediated apoptosis in HIV-1 infected patients. J Med Virol 80:1933–1940. doi:10.1002/jmv.21305.
    OpenUrlCrossRefPubMed
  39. 39.↵
    1. Nattermann J,
    2. Nischalke H-D,
    3. Kupfer B,
    4. Rockstroh J,
    5. Hess L,
    6. Sauerbruch T,
    7. Spengler U
    . 2003. Regulation of CC chemokine receptor 5 in hepatitis G virus infection. AIDS 17:1457–1462. doi:10.1097/00002030-200307040-00006.
    OpenUrlCrossRefPubMedWeb of Science
  40. 40.↵
    1. Rydze RT,
    2. Xiang J,
    3. McLinden JH,
    4. Stapleton JT
    . 2012. GB virus type C infection polarizes T-cell cytokine gene expression toward a Th1 cytokine profile via NS5A protein expression. J Infect Dis 206:69–72. doi:10.1093/infdis/jis312.
    OpenUrlCrossRefPubMed
  41. 41.↵
    1. Schwarze-Zander C,
    2. Neibecker M,
    3. Othman S,
    4. Tural C,
    5. Clotet B,
    6. Blackard JT,
    7. Kupfer B,
    8. Luechters G,
    9. Chung RT,
    10. Rockstroh JK,
    11. Spengler U
    . 2010. GB virus C coinfection in advanced HIV type-1 disease is associated with low CCR5 and CXCR4 surface expression on CD4(+) T-cells. Antivir Ther 15:745–752. doi:10.3851/IMP1602.
    OpenUrlCrossRefPubMed
  42. 42.↵
    1. Stapleton JT,
    2. Chaloner K,
    3. Martenson JA,
    4. Zhang J,
    5. Klinzman D,
    6. Xiang J,
    7. Sauter W,
    8. Desai SN,
    9. Landay A
    . 2012. GB virus C infection is associated with altered lymphocyte subset distribution and reduced T cell activation and proliferation in HIV-infected individuals. PLoS One 7:e50563–e50563. doi:10.1371/journal.pone.0050563.
    OpenUrlCrossRefPubMed
  43. 43.↵
    1. Xiang J,
    2. George SL,
    3. Wünschmann S,
    4. Chang Q,
    5. Klinzman D,
    6. Stapleton JT
    . 2004. Inhibition of HIV-1 replication by GB virus C infection through increases in RANTES, MIP-1alpha, MIP-1beta, and SDF-1. Lancet 363:2040–2046. doi:10.1016/S0140-6736(04)16453-2.
    OpenUrlCrossRefPubMedWeb of Science
  44. 44.↵
    1. Stapleton JT,
    2. Martinson JA,
    3. Klinzman D,
    4. Xiang J,
    5. Desai SN,
    6. Landay A
    . 2013. GB virus C infection and B-cell, natural killer cell, and monocyte activation markers in HIV-infected individuals. AIDS 27:1829–1832. doi:10.1097/QAD.0b013e328363089f.
    OpenUrlCrossRefPubMedWeb of Science
  45. 45.↵
    1. Vogel G
    . 28 August 2014. Ebola's heavy toll on study authors. ScienceInsider http://news.sciencemag.org/health/2014/08/ebolas-heavy-toll-study-authors.
  46. 46.
    Developmental Core Team R. 2014. R: a language and environment for statistical computing. R Development Core Team, Vienna, Austria.
View Abstract
PreviousNext
Back to top
Download PDF
Citation Tools
GB Virus C Coinfections in West African Ebola Patients
Michael Lauck, Adam L. Bailey, Kristian G. Andersen, Tony L. Goldberg, Pardis C. Sabeti, David H. O'Connor
Journal of Virology Jan 2015, 89 (4) 2425-2429; DOI: 10.1128/JVI.02752-14

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Print

Alerts
Sign In to Email Alerts with your Email Address
Email

Thank you for sharing this Journal of Virology article.

NOTE: We request your email address only to inform the recipient that it was you who recommended this article, and that it is not junk mail. We do not retain these email addresses.

Enter multiple addresses on separate lines or separate them with commas.
GB Virus C Coinfections in West African Ebola Patients
(Your Name) has forwarded a page to you from Journal of Virology
(Your Name) thought you would be interested in this article in Journal of Virology.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Share
GB Virus C Coinfections in West African Ebola Patients
Michael Lauck, Adam L. Bailey, Kristian G. Andersen, Tony L. Goldberg, Pardis C. Sabeti, David H. O'Connor
Journal of Virology Jan 2015, 89 (4) 2425-2429; DOI: 10.1128/JVI.02752-14
del.icio.us logo Digg logo Reddit logo Twitter logo CiteULike logo Facebook logo Google logo Mendeley logo
  • Top
  • Article
    • ABSTRACT
    • TEXT
    • ACKNOWLEDGMENTS
    • FOOTNOTES
    • REFERENCES
  • Figures & Data
  • Info & Metrics
  • PDF

Related Articles

Cited By...

About

  • About JVI
  • Editor in Chief
  • Editorial Board
  • Policies
  • For Reviewers
  • For the Media
  • For Librarians
  • For Advertisers
  • Alerts
  • RSS
  • FAQ
  • Permissions
  • Journal Announcements

Authors

  • ASM Author Center
  • Submit a Manuscript
  • Article Types
  • Ethics
  • Contact Us

Follow #Jvirology

@ASMicrobiology

       

 

JVI in collaboration with

American Society for Virology

ASM Journals

ASM journals are the most prominent publications in the field, delivering up-to-date and authoritative coverage of both basic and clinical microbiology.

About ASM | Contact Us | Press Room

 

ASM is a member of

Scientific Society Publisher Alliance

 

American Society for Microbiology
1752 N St. NW
Washington, DC 20036
Phone: (202) 737-3600

Copyright © 2021 American Society for Microbiology | Privacy Policy | Website feedback

Print ISSN: 0022-538X; Online ISSN: 1098-5514